COMPANY HISTORY

Burzynski Research Institute (BRI ) is a biotech company based in Houston, Texas U.S.A. engaged in research and development of targeted gene therapies (antineoplastons) for the treatment of cancer. The company was formed in 1983 by Stanislaw R. Burzynski, M.D., Ph.D., who continues to serve as Chairman of the Board and C.E.O.

OUR VISION OUR MISSION
BRI will be a recognized leader in the war against cancer. We will transform progress into promise for cancer patients, providing a more natural way to fight and, ultimately, prevent the disease. To research, develop and manufacture the next generation of cancer therapeutics and make them available to cancer patients worldwide.